- Home
- LRE vs BOLD Comparison
LRE vs BOLD Comparison
Compare LRE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- BOLD
- Stock Information
- Founded
- LRE 2001
- BOLD 2018
- Country
- LRE Japan
- BOLD United States
- Employees
- LRE N/A
- BOLD N/A
- Industry
- LRE
- BOLD
- Sector
- LRE
- BOLD
- Exchange
- LRE Nasdaq
- BOLD Nasdaq
- Market Cap
- LRE 20.5M
- BOLD 24.4M
- IPO Year
- LRE 2023
- BOLD 2024
- Fundamental
- Price
- LRE $1.56
- BOLD $1.15
- Analyst Decision
- LRE
- BOLD Buy
- Analyst Count
- LRE 0
- BOLD 4
- Target Price
- LRE N/A
- BOLD $4.00
- AVG Volume (30 Days)
- LRE 80.4K
- BOLD 79.9K
- Earning Date
- LRE 07-30-2015
- BOLD 11-06-2025
- Dividend Yield
- LRE N/A
- BOLD N/A
- EPS Growth
- LRE N/A
- BOLD N/A
- EPS
- LRE N/A
- BOLD N/A
- Revenue
- LRE $110,330,328.00
- BOLD N/A
- Revenue This Year
- LRE N/A
- BOLD N/A
- Revenue Next Year
- LRE N/A
- BOLD N/A
- P/E Ratio
- LRE N/A
- BOLD N/A
- Revenue Growth
- LRE 3.92
- BOLD N/A
- 52 Week Low
- LRE $1.00
- BOLD $1.00
- 52 Week High
- LRE $2.49
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- LRE 53.48
- BOLD 49.88
- Support Level
- LRE $1.29
- BOLD $1.13
- Resistance Level
- LRE $1.44
- BOLD $1.16
- Average True Range (ATR)
- LRE 0.14
- BOLD 0.04
- MACD
- LRE 0.01
- BOLD 0.00
- Stochastic Oscillator
- LRE 91.89
- BOLD 62.50
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.